BrainsWay Ltd., a global leader in advanced noninvasive treatment of brain disorders, has started the distribution of its first 10 Deep Transcranial Magnetic Stimulation (Deep TMS) devices for ending smoking addiction across the United States t0 the following clinics:
• Advanced Mental Health Care in Palm Beach, FL
• Brooklyn Minds in New York, NY
• Delray Center for Healing in Delray Beach, FL
• Greenbrook TMS NeuroHealth in Richmond Heights, MO
• Houston TMS Therapeutics in Bellaire, TX
• Kadima Neuropsychiatry Institute in La Jolla, CA
• Medical University of South Carolina (MUSC) in Charleston, SC
• Novus TMS in Tuscaloosa, AL
• PsyCare Inc. in Charleston, WV
• TMS NW in Vancouver, WA
Last month, April 2021, BrainsWay treated its 100,000th Patient with Deep Transcranial Magnetic Stimulation (Deep TMS) for depression and OCD. There are currently more than 600 BrainsWay Deep TMS Systems installed in private clinics, outpatient facilities, and hospitals globally.
“As scientific founders of BrainsWay, it is rewarding to see the Company achieve this milestone and to witness the positive impact this groundbreaking technology has had on so many patients and families,” said Prof. Abraham Zangen, Co-Founder and Board Director of BrainsWay, and Yiftach Roth, Ph.D., Co-Founder and Chief Scientific Officer of BrainsWay. “This novel technology can help millions of patients in the coming years, and we are honored to be part of providing successful and noninvasive mental health solutions to those who need them most.”
More FDA Clearance
BrainsWay also received FDA clearance for their three-minute Theta Burst Treatment Protocol for Major Depressive Disorder. The BrainsWay Theta Burst protocol will be immediately available on all BrainsWay systems already installed which will enable many patients and providers to offer significantly shorter treatment sessions.
“The addition of Theta Burst to the available protocols further demonstrates BrainsWay’s commitment to expanding the utility of the BrainsWay Deep TMS system,” said Moria Ankri, Vice President of Research & Development. “This protocol shows that innovation need not be revolutionary or radical to have a positive effect on peoples’ lives. Having a three-minute option for patients has the potential to expand access to care by providing patients with added flexibility in selecting courses of treatment that may fit better with their lifestyle.”
The technology received FDA clearance for the treatment of major depressive disorder (MDD) in 2013 and for the treatment of obsessive-compulsive disorder (OCD) in 2018. The recently FDA-cleared aid for short-term smoking cessation offers a noninvasive treatment that administers electromagnetic pulses using BrainsWay’s patented H4-coil through a cushioned helmet, stimulating neurons in brain structures associated with addiction.
“Tobacco smoking is one of the leading causes of preventable disease and death throughout the world,” said Christopher von Jako, Ph.D., President and Chief Executive Officer of BrainsWay. “We have seen lives drastically changed after undergoing Deep TMS treatment and are eager to bring this same hope to those who desire to quit smoking. Research shows that there is often comorbidity between tobacco use and mental disorders, and the COVID-19 pandemic has exacerbated both. Many patients have given up trying to quit, but now, with a noninvasive option like Deep TMS, we are hopeful they are able to take that step.”
Deep TMS is the first FDA-cleared noninvasive treatment in the addiction space for any TMS device, and currently serves as the only TMS platform technology with clinical outcome data for multiple brain disorders. In 2019, a double-blind, sham-controlled, multicenter randomized controlled trial of 262 patients found Deep TMS to be an effective treatment, significantly improving the continuous quit rate, as well as reducing craving and the average number of cigarettes smoked per week. Participants in the study were highly addicted to smoking with a history of smoking an average of over 26 years and multiple failed attempts to quit.
In honor of Mental Health Awareness Month, Christopher von Jako, President & CEO, BrainsWay, rang the NASDAQ closing bell on Wednesday, May 5, 202. The ceremony can be viewed at https://www.nasdaq.com/events/brainsway-ltd.-rings-the-closing-bell
About BrainsWay (NASDAQ & TASE: BWAY)
BrainsWay is a global leader in advanced noninvasive neurostimulation treatments for mental health disorders. The Company is boldly advancing neuroscience with its proprietary Deep Transcranial Magnetic Stimulation (Deep TMS) platform technology to improve health and transform lives. BrainsWay is the first and only TMS company to obtain three FDA-cleared indications backed by pivotal studies demonstrating clinically proven efficacy. Current indications include major depressive disorder, obsessive-compulsive disorder, and smoking addiction. The Company is dedicated to leading through superior science and building on its unparalleled body of clinical evidence. Additional clinical trials of Deep TMS in various psychiatric, neurological, and addiction disorders are underway. Founded in 2003, with offices in Cresskill, NJ and Jerusalem, Israel, BrainsWay is committed to increasing global awareness and broad access to Deep TMS. For the latest news and information about BrainsWay, please visit www.brainsway.com.
SVP and General Manager, BrainsWay
HadarL at brainsway.com
About JLM- BioCity
News on the many life science and healthcare companies in the Jerusalem area can be seen at https://jlm-biocity.org/jlm-biocity-innovations/
JLM-BioCity is a non-profit organization focused on developing and excelling Jerusalem’s bio-community.
We invite you, researcher, professional, investor and executive to become part of our vision, in building Jerusalem’s Biomed eco-system.
If you want your Company featured in our blogs , news releases, please contact: info at jlm-biocity.org